In June 2000, Daiichi Sankyo Company opened a new pharmaceutical plant in Beijing.
The facility is located in the Beijing economic and technological development area in China. It was constructed by Daiichi Pharmaceutical Company, which merged with Sankyo Company on 1 July 2006.
The merged entities began the acquisition by forming a joint holding company on 28 September 2005 and the European part of the merger was finalised on 31 March 2007.
In November 2011, Daiichi Sankyo established Daiichi Sankyo China in Shanghai. The company is a 100% owned Chinese subsidiary and manages the Bejing and Shanghai operations.
Daiichi Sankyo is one of the top three pharmaceutical companies in Japan and one of the top 20 pharmaceutical companies worldwide. It has around 2,300 medical representatives in 33 locations throughout Europe and the US.
The factory began construction in Beijing’s economic and technological development area in October 1998. The project was completed in June 2000, with the construction of an office and quality control building, as well as solid-pharmaceutical facilities, a warehouse and engineering buildings.
In addition to the solid pharmaceutical production line, Daiichi completed a new injectable pharmaceuticals line in 2002.
The main products manufactured in the plant are Cravit tablets, Translon tablets, Tarivid tablets and the Cravit injection. For the production phase, Daiichi has strengthened its quality assurance (QA) systems and reduced product defects through the methodical introduction of good manufacturing practices (GMP) procedures devised in-house.
To increase manufacturing efficiency, the factories of all Daiichi Group companies worked to sharpen their focus on key technological fields and shift operations involving other technologies to factories better positioned to handle them.
The company also created a unified information management system for all its factories and R&D facilities, steadily increasing the number and upgrading the qualifications of its technical and quality assurance specialists.
In addition, the Daiichi Group built a manufacturing system that is compliant with international QA standards to ensure a cost-efficient, stable supply of all the company’s products, from prescription drugs to diagnostic reagents.
The site of the plant extension is 47,800m², with a building space of 6,900m² and a floor space of 11,400m².
The facilities built comprise an administrative/quality control building, solid pharmaceutical production, injectable pharmaceutical production, warehouse, engineering buildings, and utility facilities.
The plant capacity for solid pharmaceuticals is 200 million tablets a year.
In addition to the current solid pharmaceutical production line, Daiichi completed a new production line for injectable pharmaceuticals of plastic bottle packages in 2002.
The injection production capacity for plastic bottle packages is 2 million bottles a year.
Equipped with production equipment and quality control (QC) systems, DPB started sales of Cravit tablets in 2001.
The total investment in the plant was approximately $65.5m.
Lykan Bioscience opened a purpose-built SMART Manufacturing™ facility for developing cell-based therapies in Hopkinton, Massachusetts, US, in September 2020. The…
Samsung Biologics is planning to expand its manufacturing facilities with the construction of its fourth biopharmaceutical manufacturing plant, P4-Super Plant,…
Evergreen Theragnostics, a radiopharmaceutical contract development and manufacturing organisation (CDMO) based in New Jersey, US, is developing a state-of-the-art radiopharmaceutical…
Aphena Pharma Solutions announced the expansion of its Solid Dose Division in Cookeville, Tennessee, US in September 2020. The project…